Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed renal cell carcinoma, including 1 of the following subtypes:~  * Clear cell~ * Papillary~ * Medullary~* Metastatic disease~* Not amenable to curative surgery~* No CNS metastases~PATIENT CHARACTERISTICS:~Performance status~* Karnofsky 70-100%~Life expectancy~* More than 6 months~Hematopoietic~* Not specified~Hepatic~* Bilirubin \< 2 times upper limit of normal (ULN)~* AST or ALT \< 4 times ULN~Renal~* Creatinine clearance \> 50 mL/min~Cardiovascular~* LVEF \> 35%~* No symptomatic congestive heart failure~Pulmonary~* DLCO \> 40% of predicted OR~* Total lung capacity or FEV_1 \> 30% of predicted~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 30 days since prior biologic therapy~Chemotherapy~* More than 30 days since prior chemotherapy~Radiotherapy~* More than 30 days since prior radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).